GlassScriptPhysician profile
Justin K Kwon
NPI 1881020295
$9,231.64
in general payments reported to CMS, 2019-2025
42 companies · $1,891 in 2025
The $1,891 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,404 · 2022: $2,226 · 2023: $1,547 · 2024: $2,163 · 2025: $1,891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,535 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,535.47 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,275.57 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $782.78 | 2021-2025 | |
| Amgen INC. | $774.54 | 2021-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $677.38 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $578.19 | 2021-2025 | Ozempic, Rybelsus |
| Scilex Pharmaceuticals INC. | $419.68 | 2021-2025 | Ztlido |
| Amarin Pharma, INC. | $393.16 | 2021-2023 | |
| Gilead Sciences, INC. | $385.30 | 2022-2025 | Vemlidy |
| Sumitomo Pharma America, INC. | $371.91 | 2024-2025 | Gemtesa |
| Astellas Pharma US INC | $312.50 | 2021-2025 | Veozah |
| Lilly USA, LLC | $308.98 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $275.20 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $265.10 | 2024-2025 | Zenpep |
| Ibsa Pharma INC. | $240.04 | 2021-2024 | Licart, Tirosint, Tirosint |
| Ardelyx, INC. | $223.65 | 2023-2025 | Ibsrela |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $217.99 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $204.95 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.92 | 2021-2025 | Jardiance |
| Exact Sciences Corporation | $173.84 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $147.74 | 2025 | Ams 700, General - Pain Management |
| Eisai INC. | $115.52 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $96.71 | 2023-2024 | Horizant, Horizant |
| Vivus LLC | $82.35 | 2021-2025 | Pancreaze |
| Dexcom, INC. | $81.82 | 2022-2025 | Dexcom G6 Transmitter |
| Arbor Pharmaceuticals, INC. | $79.91 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $72.05 | 2021-2024 | Zoryve |
| Xeris Pharmaceuticals, INC. | $64.53 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Radius Health, INC. | $59.18 | 2024 | Tymlos |
| Takeda Pharmaceuticals U.S.A., INC. | $58.10 | 2021 | |
| Corcept Therapeutics | $43.29 | 2023-2024 | Korlym |
| Sunovion Pharmaceuticals INC. | $40.07 | 2021 | |
| Merck Sharp & Dohme LLC | $33.94 | 2023-2025 | Dificid, Gardasil 9, Capvaxive |
| Almatica Pharma LLC | $29.13 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.90 | 2025 | Xifaxan |
| Invivyd INC | $21.15 | 2025 | Pemgarda |
| Embecta Corp. | $19.81 | 2024 | |
| Averitas Pharma INC. | $19.24 | 2024 | Qutenza |
| Esperion Therapeutics, INC. | $16.77 | 2024 | Nexletol |
| Abbott Laboratories | $16.58 | 2022 | |
| Glaxosmithkline, LLC. | $16.37 | 2023 | Shingrix |
| Horizon Therapeutics Plc | $15.90 | 2021 | |
| Corium, LLC | $15.90 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Kwon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.